TEM
Tempus AIDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Execution on enterprise partnerships, successful FDA clearances, and accelerated dataset monetization drive sustained revenue growth, improved operating leverage, and multiple expansion.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
Clinical validation or regulatory setbacks
Momentum
39
Value
41
Sentiment
43
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $44.12 · Bull $68.39 · Bear $28.24
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2025-10-10 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $66.57
Why
Momentum39 · Δ7d -31.4
Value41 · Δ7d +0.1
Sentiment43 · Δ7d +10.5
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
39
26% active weight
Current posture
7d trendSoftening
Δ7d
-31.4
Δ21d
+0.6
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
43
34% active weight
Current posture
7d trendImproving
Δ7d
+10.5
Δ21d
+12.6
Why this grade
Composite grade D. Momentum 38.9 / Value 41.1 / Sentiment 43.2
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$8.8B
Beta
-
Shares Out
179.56M
P/E (TTM) · Derived
-34.8
P/S (TTM)
10.41
P/FCF (TTM) · Derived
-40.77
Rev YoY
+36.1%
EPS YoY
+78.0%
Gross Margin
+62.2%
Op Margin
-23.0%
Net Debt
$572.13M
Current Ratio
3.31
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology